CliffBio
small molecule

NAROPIN

ROPIVACAINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameNAROPIN
Active ingredientROPIVACAINE HYDROCHLORIDE
Strength50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formSOLUTION
RouteINJECTION
ModalitySmall molecule
FDA approvalMay 1998
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.